Xiaofeng Chen
A5100352373- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Cancer Mechanisms and Therapy
- Gastrointestinal Tumor Research and Treatment
- Cancer Genomics and Diagnostics
- Terahertz technology and applications
- Lung Cancer Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Lung Cancer Research Studies
- Tracheal and airway disorders
- Pleural and Pulmonary Diseases
- RNA modifications and cancer
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging and Pathology Studies
- PI3K/AKT/mTOR signaling in cancer
- Cancer-related molecular mechanisms research
- Inflammatory Biomarkers in Disease Prognosis
- Plasmonic and Surface Plasmon Research
Nanjing Medical University
2016-2025
Jiangsu Province Hospital
2016-2025
Ningbo University
2025
Sichuan University
2024
State Key Laboratory of Biotherapy
2024
Nanjing University
2014-2024
National Laboratory of Solid State Microstructures
2024
Fujian Medical University
2013-2024
Fujian Provincial Cancer Hospital
2020-2024
Taizhou People's Hospital
2023
Background The standard neoadjuvant treatments in patients with esophageal squamous cell carcinoma (ESCC) still have either poor safety or efficacy. Better therapies are needed China. Methods This was an open-label, single-arm, phase 2 trial. Patients potentially resectable ESCC (cT1b-3, Nany, M0 T4a, N0-1, M0) received preoperative intravenous sintilimab plus triplet chemotherapy (liposomal paclitaxel, cisplatin, and S-1) every 3 weeks for two cycles. primary endpoints were surgical...
Cancer is a disease of complex genetic alterations, and comprehensive diagnosis beneficial to match each patient appropriate therapy. However, acquisition representative tumor samples invasive sometimes impossible. Circulating DNA (ctDNA) promising tool use as non-invasive biomarker for cancer mutation profiling. Here we implemented targeted next generation sequencing (NGS) with customized gene panel 382 cancer-relevant genes on 605 ctDNA in multiple types. Overall, tumor-specific mutations...
Background Immune checkpoint inhibitors monotherapy has been studied in patients with advanced biliary tract cancer (BTC). The aim of this study was to assess the efficacy and safety camrelizumab, plus gemcitabine oxaliplatin (GEMOX) as first-line treatment BTC explored potential biomarkers associated response. Methods In single-arm, open-label, phase II study, we enrolled stage IV patients. Participants received camrelizumab (3 mg/kg) (800 mg/m 2 ) (85 ). Primary endpoints were 6-month...
Brain metastases (BM) of colorectal cancer (CRC) are rare but lethal, and an understanding their genomic landscape is lacking. We conduct analysis whole-exome sequencing (WES) whole-genome (WGS) data on 19 trios patient-matched BMs, primary CRC tumors, adjacent normal tissue. Compared with CRC, BM exhibits elevated mutational signatures homologous recombination deficiency (HRD) mismatch repair (MMRD). Further reveals two DNA damage response (DDR) could emerge early enhanced in tissues...
Abstract Patients with advanced gastric cancer typically face a grim prognosis. This phase 1a (dose escalation) and 1b expansion) study investigated safety efficacy of first-line camrelizumab plus apatinib chemotherapy for or gastroesophageal junction adenocarcinoma. The primary endpoints included maximum tolerated dose (MTD) in objective response rate (ORR) across 1b. Phase tested three regimens camrelizumab, apatinib, oxaliplatin, S-1. Dose regimen 1: 200 mg on day 1, 250 every other day,...
To determine whether radiomics features based on contrast-enhanced CT (CECT) can preoperatively predict lymphovascular invasion (LVI) and clinical outcome in gastric cancer (GC) patients.In total, 160 surgically resected patients were retrospectively analyzed, seven predictive models constructed. Three built from arterial (A), venous (V) combination of two phase (A + V) images. Then, three Radscores (A-Radscore, V-Radscore A V-Radscore) obtained. Another four constructed by the risk factors...
Abstract The positive results of the apatinib phase III trial have cast new light on treatment for patients with advanced gastric cancer (GC). However, in terms safety, toxicities may lead to a dose modification or interruption. Therefore, proper intervention is urgently needed help benefit from treatment. In this study, we found that promoted autophagy activation via upregulation ATG7 expression and inhibition enhanced apatinib-induced apoptosis. With microRNA circular RNA-sequencing...
Immune checkpoint inhibitors plus antiangiogenic tyrosine kinase may offer a first-line treatment for advanced hepatocellular carcinoma (HCC). In this phase 2 trial [registered with clinicaltrials.gov (NCT04052152)], we investigated the safety and efficacy of anti-PD-1 antibody sintilimab TKI anlotinib HCC.Pathologically-proven HCC patients received (200 mg) on day 1 (12 once daily days to 14 every 3 weeks, run-in first six participants assess dose-limiting toxicities (DLTs). The primary...
Thymic epithelial tumors (TETs) are a relatively rare type of thoracic tumor, accounting for less than 1% all tumors. The incidence TETs is about 3.93/10000 in China, slightly higher that European and American countries. For resectable TETs, complete surgical resection recommended. Radiotherapy or chemotherapy may be used as postoperative adjuvant treatment. Treatment advanced, unresectable consist mainly radiotherapy chemotherapy, but there lack standard first- second-line treatment...
Abstract Lessons Learned Patients with metastatic colorectal cancer good performance status or no liver metastasis could benefit from apatinib. Circulating tumor DNA abundance may be a predictor in serial monitoring of load. Background Apatinib, an oral vascular endothelial growth factor (VEGF) receptor-2 inhibitor, has been approved as third-line treatment for gastric China. The aim this study was to evaluate the efficacy and safety apatinib, patients refractory after failure two more lines...
We demonstrate the capability of terahertz (THz) time-domain spectroscopy (TDS) to quantify glucose level in ex vivo freshly diabetic's blood. By investigating THz spectra different human blood, we find out absorption coefficients reflect a high sensitivity With quantitative analysis 70 patients, that and blood levels perform linear relationship. A comparative experiment between measurement glucometers is also conducted with another 20 samples, results confirm relative error as less 15%. Our...
Background Recently, immunotherapy with immune checkpoint inhibitors (ICIs) has shown promising efficacy in biliary tract cancer (BTC), which includes gallbladder (GBC) and cholangiocarcinoma (CHOL). Understanding the association between outcomes genomic profile of advanced BTC may further improve clinical benefits from immunotherapy. Methods Genomic tumor DNA was isolated 98 Chinese patients used for targeted next-generation sequencing 416 cancer-related genes to identify alterations common...
The molecular mechanisms that underpin invasive ductal breast cancer (IDC) invasion and metastasis are incompletely understood. oncogene, mouse double minute 2 (MDM2), has been implicated in the pathogenesis of numerous cancers, where it stimulates expression matrix metalloproteinase 9 (MMP9), an important enzyme breakdown extracellular matrix. However, its role remains poorly This study assessed clinical significance MDM2 IDC used vitro assays to determine roles MDM2. Immunohistochemical...
Background: Gallbladder cancer (GBC) is often diagnosed at an advanced stage with limited therapeutic options and poor prognosis. The five-year survival rate of this when below 5%, the median time less than a year standard gemcitabine-based chemotherapy. Survival benefit second-line treatment unknown. Thus, there urgent need for novel strategies targeted therapy based on next generation sequencing (NGS) may be value. Methods: Comprehensive genomic profiling (CGP) was performed NGS panel...
Malignant pleural mesothelioma (MPM) is a malignant tumor originating from the pleura, and its incidence has been increasing in recent years. Due to insidious onset strong local invasiveness of MPM, most patients are diagnosed late stage early screening treatment for high-risk populations crucial. The MPM mainly includes surgery, chemotherapy, radiotherapy. Immunotherapy electric field therapy have also applied, leading further improvements patient survival. Mesothelioma Group Yangtze River...
Abstract The fusion genes NRG1 and NRG2, members of the epidermal growth factor (EGF) receptor family, have emerged as key drivers in cancer. Upon fusion, retains its EGF-like active domain, binds to ERBB ligand triggers intracellular signaling cascades, promoting uncontrolled cell proliferation. incidence gene varies across cancer types, with lung being most prevalent at 0.19 0.27%. CD74 SLC3A2 are frequently observed partners. RNA-based next-generation sequencing is primary method for...